Medicine & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affitech
Affitech to play key role in embryonal tumor pipeline project
October 13th, 2006
Affitech announced that it has been selected to participate in the new European Union E.E.T. Pipeline project to identify fully human therapeutic antibody candidates for Embryonal Tumors (ET) by using its unique antibody discovery platform. The E.E.T. Pipeline project is a multidisciplinary consortium of leading European institutions and SME (Small and Medium Enterprise)s, which the E.U. is funding with EUR 4 million for developing new methods of diagnosis and treatment for ET. Such methods would be based on gene expression profiling of tumors and would include other post-genomic investigative technologies. The EU has taken this initiative since Embryonal Tumors are...
Source: Medicine & Law Weekly (2006-10-13)
|
